New York, NY -- June 07, 2018 --- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the "Company," or AMBS), a US-based, JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today provided an update to the marketplace on its capital formation plans for its wholly-owned subsidiary Elto Pharma, Inc. Amarantus recently received an independent third-party valuation report which valued the Parkinson's disease levodopa-induced dyskinesia (PD-LID) indication for Eltoprazine in the US and Europe at $316 million. Amarantus management has outlined two distinct paths for Elto Pharma to extract as much value for the Eltoprazine asset for Amarantus as possible: 1) standalone private funding followed by a US or Hong Kong-based IPO, or 2) a business combination with an established clinical-stage biopharmaceutical company with strong management and an exceptional pipeline in which Amarantus could become a significant shareholder. Amarantus expects to make a final determination on the capital formation plan for Elto Pharma in the summer of 2018.